Propanc Health Group Corporation — Form 10-Q
Reporting period: Three and six months ended December 31, 2013 (fiscal 2014 second quarter); filed February 14, 2014. The unaudited statements cover the development-stage company and its Australian subsidiary. The filing identifies the company as a cancer-treatment research and development business with no products in clinical trials or available for sale.
Financial results and position
| Metric | Three months ended Dec. 31 | Six months ended Dec. 31 |
|---|---|---|
| Revenue | $0 in 2013 and 2012 | $0 in 2013 and 2012 |
| Operating expenses | $225,454 in 2013; $446,897 in 2012 | $534,024 in 2013; $942,760 in 2012 |
| Net income (loss) | $26,399 in 2013; $(387,753) in 2012 | $(545,112) in 2013; $(880,318) in 2012 |
| Operating cash flow | Not presented for the quarter | $(101,820) in 2013; $(77,898) in 2012 |
- Quarterly net income included a $227,616 gain from remeasuring warrant derivative liability; it was not operating revenue. Without revenue, gross profit and operating margins are not meaningful.
- Six-month R&D expense was $0. Management attributed six-month operating expenses mainly to approximately $270,000 of stock-based compensation, $120,000 of professional fees and $82,000 of payroll.
- At December 31, cash was $736; current assets were $11,923 and current liabilities $1,062,344, producing a working-capital deficit of $1,050,421. Stockholders’ deficit was also $1,050,421; accumulated development-stage deficit was $17,268,465.
- Current liabilities included $311,455 accounts payable, $318,285 accrued expenses and other payables, $116,552 in loans from directors and an officer, $55,608 due to directors, $23,742 in other loans, $19,550 convertible debt net of discount, and a $163,559 warrant derivative liability. No long-term debt is shown.
- Six-month financing cash flow was $90,859, including approximately $128,000 of loan proceeds offset by approximately $37,000 of repayments. No investing cash flow was reported.
Changes, outlook and risks
- Six-month operating expenses and net loss were lower than the prior-year period, while cash used in operations increased. The company continued to report no current-period revenue.
- Management estimated approximately $7.5 million would be needed over the next 12–24 months to fund operations and development. It said financing efforts were underway, but warned that failure to obtain funds could force delays, reductions or cessation of programs or operations.
- The filing explicitly states that the company does not have enough cash to continue operations for the next 12 months and that substantial doubt exists about its ability to continue as a going concern. Elsewhere, management says existing cash plus additional financing could fund operations until December 2014; these liquidity statements should be reconciled.
- The lead product remained in preclinical work; no product had reached clinical trials. Commercial success depends on development, financing, patent progress and eventual sales. The filing reports a South African patent grant and national-phase filings or provisional filings in multiple other markets.
- Director and officer loans were past due and in default, as were loans from two unrelated parties bearing 10% interest. A $139,680 debenture bears 12% interest, matures December 31, 2015, and has 3 million repricing warrants; the lender may convert at $0.0698 per share upon company default. Warrant fair value is a Level 3 estimate.
- In January and February 2014, the company reported additional advances and loans totaling approximately $43,470. These subsequent-event borrowings were unsecured or related-party financing, and included a 10% third-party loan.
- Disclosure controls were deemed ineffective because the small staff did not provide sufficient segregation of duties. Management planned to address the weakness by hiring accounting personnel when resources permitted. The filing reports no pending or threatened material litigation and no off-balance-sheet arrangements.
Important facts to verify
- Available cash, near-term cash requirements, and the apparent inconsistency in management’s statements about funding through December 2014 versus insufficient funds for the next 12 months.
- Ability to raise the estimated $7.5 million, and the terms and dilution implications of financing, convertible debt and repricing warrants.
- Current status and maturity/default terms of related-party and unrelated-party loans, and subsequent-event borrowings.
- Basis and cash receipt timing for the $48,451 six-month income-tax benefit, and the assumptions underlying the Level 3 warrant valuation and reported quarterly profit.
- Preclinical and patent-development milestones, and whether the disclosed lack of R&D expense reflects the actual level of development activity.
- Remediation of the material weakness in disclosure controls; the filing reports 72,684,768 common shares outstanding as of February 10, 2014.